8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
Biogen reports 11% revenue growth and raises 2026 EPS guidance floor
Filed with the SEC on · Summarized by InvestorsBot
Biogen reported third-quarter 2026 revenue of $2.8 billion, up 11% year over year, while Growth Portfolio revenue rose 49% to $1.26 billion, helped by the first full quarter of products acquired from Apellis in May. GAAP diluted EPS was a loss of $0.14, compared with non-GAAP diluted EPS of $2.62 after $284 million in acquired in-process R&D, upfront and milestone expenses; Biogen raised its full-year 2026 non-GAAP EPS guidance range to $12.20-$13.00 from $12.00-$13.00.